Edwards Lifesciences Q2 2021 Earnings Report
Key Takeaways
Edwards Lifesciences reported a strong second quarter with sales up 49% to $1.4 billion and underlying sales growth of 44%. TAVR sales exceeded expectations, growing 52%. The company raised its full-year sales guidance to $5.2 to $5.4 billion and adjusted EPS guidance to the high end of the previous $2.07 to $2.27 range.
Sales rebounded and grew 49 percent to $1.4 billion; underlying sales grew 44 percent
TAVR sales exceeded expectations and grew 52 percent; underlying sales grew 48 percent
EPS was $0.78; adjusted EPS was $0.64
Continued progress on five pivotal trials in TMTT
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Forward Guidance
The company now expects full year 2021 sales of $5.2 to $5.4 billion versus previous guidance of $4.9 to $5.3 billion. The company is raising full year 2021 adjusted earnings per share guidance to the high end of the previous $2.07 to $2.27 range. For the third quarter of 2021, the company projects sales to be between $1.29 and $1.37 billion, and adjusted EPS of $0.50 to $0.56.
Revenue & Expenses
Visualization of income flow from segment revenue to net income